Edit
Balt
https://www.balt-corp.com/en/balt-a-pioneer-in-stroke-treatment/Last activity: 20.12.2024
Active
BALT is a world leader in the design and manufacture of interventional neuroradiology devices to treat neurovascular pathologies (strokes, aneurysms, AVMs). By placing innovation at the center of its model, the company maintains its leading position in the neuroradiology field worldwide.
Since its creation in 1977 by Leopold Plowiecki, and at the instigation of Nicolas Plowiecki, his son, at the helm of the group from 2001 to 2018, BALT has been a leading player throughout the evolution of interventional radiology. Its unique model has enabled the company to always keep one step ahead and to provide cutting-edge therapeutic solutions and devices.
The success of BALT relies on the originality of several key assets:
• Strong and ongoing innovation to meet the expectations of the medical community: BALT’s many inventions are testimony to the company’s major influence on the progress of interventional neuroradiology. They include the flow-dependent microcatheter (MAGIC, 1987), as well as the intracranial braided stent (LEO in 2003 and LEO+ in 2007 and LEO+Baby in 2012), the stentriever (CATCH in 2005, CATCH+ in 2012 and CATCH VIEW in 2018) and the flow-diverter (SILK in 2006, SILK+ in 2012, and SILK VISTA BABY in 2018).
• Sustainable industry recognition and industrial partnerships to serve the healthcare community and patients.
• Multidisciplinary crossover talents: in its search for the highest performing neuroradiology products, BALT has always promoted a cross-innovation approach based on complementary expertise and disciplines. From chemistry to micromechanics, the production cycle is based on interdisciplinarity and constantly pursues end-product excellence.
As of December 2018, the company is headed by Pascal Girin.
Since its creation in 1977 by Leopold Plowiecki, and at the instigation of Nicolas Plowiecki, his son, at the helm of the group from 2001 to 2018, BALT has been a leading player throughout the evolution of interventional radiology. Its unique model has enabled the company to always keep one step ahead and to provide cutting-edge therapeutic solutions and devices.
The success of BALT relies on the originality of several key assets:
• Strong and ongoing innovation to meet the expectations of the medical community: BALT’s many inventions are testimony to the company’s major influence on the progress of interventional neuroradiology. They include the flow-dependent microcatheter (MAGIC, 1987), as well as the intracranial braided stent (LEO in 2003 and LEO+ in 2007 and LEO+Baby in 2012), the stentriever (CATCH in 2005, CATCH+ in 2012 and CATCH VIEW in 2018) and the flow-diverter (SILK in 2006, SILK+ in 2012, and SILK VISTA BABY in 2018).
• Sustainable industry recognition and industrial partnerships to serve the healthcare community and patients.
• Multidisciplinary crossover talents: in its search for the highest performing neuroradiology products, BALT has always promoted a cross-innovation approach based on complementary expertise and disciplines. From chemistry to micromechanics, the production cycle is based on interdisciplinarity and constantly pursues end-product excellence.
As of December 2018, the company is headed by Pascal Girin.
Location: France, Ile-de-France, Montmorency
Employees: 201-500
Founded date: 1977
Investors 1
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
Mentions in press and media 2
| Date | Title | Description |
| 20.12.2024 | Balt secures €355 million to refinance its debt and accelerate its growth | PARIS and MONTMORENCY, France, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Balt, a global medical device leader in interventional neuroradiology, announces that it has secured €355 million in financing from a group of leading institutional investors ... |
| 21.07.2021 | Manutan International : And the champions are... Manutan announces the names of the 3 winning start-ups of the “Moov'with Manutan” programme | Following the launch in May of the 'Moov'with Manutan' programme led jointly with Moovjee which aimed to identify and support innovative start-ups in the B2B world, the Manutan and Moovjee jury met and chose the winners. On July 8, the jury... |